Accueil   Diary - News   All news Alizé Pharma reports positive results of AZP-531 on Prader-Willi syndrom

Alizé Pharma reports positive results of AZP-531 on Prader-Willi syndrom

Alizé Pharma SAALIZE NEWSLETTERS is an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases. 

 

It announces today the top-line results of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi Syndrome (PWS).

 

 

This randomized, double-blind, placebo-controlled, European multicenter study was aimed at evaluating the safety, tolerab ility and efficacy of AZP-531 administered dailysubcutaneously for 14 days on food-related behavior, versus place.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree